Travere Therapeutics Inc share price logo

Travere Therapeutics Inc Share Price

NASDAQ: TVTX

Mid Cap

$38.78

-1.51

(-3.75%)

as on

Travere Therapeutics Inc Stock Performance

as on April 22, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $38.47
    $40.30
    downward going graph

    0.80%

    Downside

    3.92%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $13.88
    $43.31
    downward going graph

    64.21%

    Downside

    11.68%

    Upside

    downward going graph

Travere Therapeutics Inc share price movements today

Previous Close
$40.29
Open
$40.30
Volume
1.3M
Day's Low - High
$38.47 - $40.30
52 Week Low - High
$13.88 - $43.31

Travere Therapeutics Inc Historical Returns

1 Month Return
+ 50.11 %
3 Month Return
+ 42.62 %
1 Year Return
+ 166.64 %
3 Year Return
+ 89.78 %
5 Year Return
+ 55.74 %

Travere Therapeutics Inc Stock Fundamentals & Key Indicators

Check Travere Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$3.8B

EPS (TTM)

1.5671

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-2.1M

Revenue (TTM)

490.7M

Profit Margin

-5.21%

Return On Equity TTM

-57.80%

Travere Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Travere Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Travere Therapeutics Inc image
Travere Therapeutics Inc
BUY$3.8B55.74%NA-5.21%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$41.3B126.09%133.478.45%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$111.7B99.85%28.6532.94%
BeiGene, Ltd. image
BeiGene, Ltd.
NA$36.5BNA128.255.37%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$79.2B47.96%18.0531.41%

Stock Returns calculator for Travere Therapeutics Inc Stock including INR - Dollar returns

The Travere Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Travere Therapeutics Inc investment value today

Current value as on today

₹2,81,735

Returns

₹1,81,735

(+181.73%)

Returns from Travere Therapeutics Inc Stock

₹1,56,651 (+156.65%)

Dollar Impact

₹25,084 (+25.08%)

Analyst Recommendation on Travere Therapeutics Inc Stock

Based on 22 analysts

BUY

72.73%

Buy

27.27%

Hold

0.00%

Sell

Based on 22 analysts, 72.73% of analysts recommend a 'BUY' rating for Travere Therapeutics Inc. Average target price of $48.21

Travere Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Travere Therapeutics Inc.

What analysts predicted

19.56%UPSIDE

Target Price

$48.21

Current Price

$38.78

Analyzed by

22 Analysts

Target

$48.21

Travere Therapeutics Inc target price $48.21, a slight upside of 19.56% compared to current price of $38.78. According to 22 analysts rating.

Travere Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Travere Therapeutics Inc Stock has increased by 312% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:312% versus previous 30 day period

Travere Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
37
45
41
54
62
74
81
114
164
129
Gross Profit
35
28
39
41
61
72
77
112
163
108
Operating Income
-92
-82
-139
-67
-56
-60
-42
-12
24
-32
EBITDA
-74
-73
-123
-56
-40
-45
-25
4
44
0
Interest Expense
2
2
2
2
2
2
2
2
2
2
Depreciation
5
9
9
10
11
12
12
14
15
18
Income Before Tax
-89
-88
-135
-69
-54
-60
-41
-12
25
-21
Income Tax Expense
0
0
0
0
0
0
0
0
0
0
Net Income
150
-90
-136
-70
-54
-60
-41
-12
25
-21
Net Profit Margin
406.35%
-200.12%
-328.86%
-130.11%
-87.14%
-80.58%
-50.44%
-11.14%
15.59%
-16.95%

Travere Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
133
154
164
175
198
131
109
145
233
490
Gross Profit
129
151
158
170
192
128
105
133
225
419
Operating Income
-58
-53
-80
-99
-176
-199
-319
-388
-323
-62
EBITDA
-38
-38
-73
-107
-145
-184
-299
-326
-265
22
Interest Expense
4
4
9
18
19
19
11
11
11
10
Depreciation
-
17
18
20
24
26
33
38
43
60
Income Before Tax
-57
-58
-101
-146
-188
-216
-331
-376
-320
-49
Income Tax Expense
-9
1
0
0
-19
0
0
0
0
0
Net Income
-47
-59
-102
-146
-169
-180
-278
-111
-321
-50
Net Profit Margin
-35.86%
-38.55%
-62.51%
-83.51%
-85.43%
-136.60%
-254.41%
-76.70%
-137.90%
-10.24%

Travere Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-88
-136
-69
-54
-60
-41
-12
25
-21
Operating Cash Flow
-70
-119
-40
-42
-35
-42
4
14
60
Investing Cash Flow
-16
104
28
46
-80
41
4
86
-104
Financing Cash Flow
0
0
0
0
139
3
1
-65
26
Change in Cash
-86
-14
-10
4
22
3
13
35
-17

Travere Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-59
-102
-146
-169
-217
-331
-376
-320
-25
Operating Cash Flow
7
-24
-58
-42
-14
-186
-280
-237
37
Investing Cash Flow
45
-203
19
-61
-137
-32
55
99
27
Financing Cash Flow
5
231
-2
127
231
117
218
139
-33
Change in Cash
58
3
-40
22
80
-104
-3
0
34

Global Institutional Holdings in Travere Therapeutics Inc

Funds
Holdings
Vanguard Group Inc
6.83%
State Street Corp
3.48%
Kynam Capital Management, LP
1.73%
Geode Capital Management, LLC
2.32%
Emerald Advisers, LLC
1.73%
See all

Travere Therapeutics Inc News & Key Events

  • img

    Today's Timeline - 13 January

    Tue, 06:03 PM

    -

    Travere Therapeutics stock tumbled 28% after FDA requested additional information on a kidney disorder drug's clinical benefits.

    Tue, 06:34 PM

    -

    Shares of Travere fell 28.2% in pre-market after issuing a corporate update and 2026 outlook.

    Tue, 11:07 PM

    -

    Biopharma stock tumbled 32% following FDA's request for more information on kidney disorder drug.

Insights on Travere Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, TVTX has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, TVTX stock has moved up by 50.1%

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, TVTX has outperformed top 5 stocks with highest market-cap in its industry

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 25.70M → -21.98M (in $), with an average decrease of 185.5% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 164.85M → 129.68M (in $), with an average decrease of 21.3% per quarter

About Travere Therapeutics Inc

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.
OrganisationTravere Therapeutics Inc
Headquarters3611 Valley Centre Drive, San Diego, CA, United States, 92130
IndustryBiotechnology
CEODr. Eric M. Dube Ph.D.
E-voting on sharesClick here to vote

Key Management of Travere Therapeutics Inc

Name

Title

Mr. Peter Heerma

Chief Commercial Officer

Dr. Jula Inrig M.D.

Chief Medical Officer

Ms. Nivi Nehra

Vice President of Corporate Communications & Investor Relations

Mr. Casey Logan

Chief Business Officer

Dr. Eric M. Dube Ph.D.

President, CEO & Director

Dr. William E. Rote Ph.D.

Chief Research Officer

Ms. Elizabeth E. Reed J.D.

Chief Legal Officer, General Counsel & Secretary

Ms. Angela Giannantonio

Chief People Officer

Mr. Christopher Cline C.F.A.

Chief Financial Officer

Ms. Sandra Calvin

SVP, Corporate Controller & Chief Accounting Officer

FAQs

What is Travere Therapeutics Inc share price today?

Travere Therapeutics Inc share price today is $38.78 as on at the close of the market. Travere Therapeutics Inc share today touched a day high of $40.3 and a low of $38.47.

What is the 52 week high and 52 week low for Travere Therapeutics Inc share?

Travere Therapeutics Inc share touched a 52 week high of $43.31 on and a 52 week low of $13.88 on . Travere Therapeutics Inc stock price today i.e. is closed at $38.78,which is 10.46% down from its 52 week high and 179.39% up from its 52 week low.

What is Travere Therapeutics Inc's market capitalisation today?

Travere Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Travere Therapeutics Inc Stock (TVTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Travere Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Travere Therapeutics Inc Shares that will get you 0.0387 shares as per Travere Therapeutics Inc share price of $38.78 per share as on April 22, 2026 at 1:29 am IST.

What is the minimum amount required to buy Travere Therapeutics Inc Stock (TVTX) from India?

Indian investors can start investing in Travere Therapeutics Inc (TVTX) shares with as little as ₹93.505 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹935.05 in Travere Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Travere Therapeutics Inc share’s latest price of $38.78 as on April 22, 2026 at 1:29 am IST, you will get 0.2579 shares of Travere Therapeutics Inc. Learn more about fractional shares .

What are the returns that Travere Therapeutics Inc has given to Indian investors in the last 5 years?

Travere Therapeutics Inc stock has given 55.74% share price returns and 23.44% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?